Repurposing Bazedoxifene for chemoprevention in pre-invasive pancreatic cancer IPMN

  • Su, Gloria (PI)

Project: Research project

Project Details

Description

PROJECT NARRATIVE We have previously identified FDA-approved Bazedoxifene as an inhibitor of the IL-6 signaling axis, a major oncogenic promoter of pancreatic cancer. Here we aim to investigate the feasibility of repurposing this well-tolerated medication as a chemopreventive therapy for patients who are at high-risk for pancreatic cancer in preclinical models. The success of our application can be immediately translated to benefit patients who can be identified as high-risk but are not sufficiently managed by current care (i.e. patients with detectable premalignant lesions, chronic pancreatitis, familial mutations).
StatusFinished
Effective start/end date12/14/2111/30/22

Funding

  • National Cancer Institute: US$238,542.00

ASJC Scopus Subject Areas

  • Cancer Research
  • Oncology

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.